NANO. Bravo likte dette..................


BARCELONA - September 12, 2019 - The biopharmaceutical company Ability Pharmaceuticals SL announced today the closing of a financing round of 3.5 million euros. The funds will allow the company to complete the phase 2 clinical trial currently ongoing in endometrial cancer and lung cancer in Spain and France and reach a licensing agreement with a pharmaceutical company to continue the development and future commercialization of the drug.